Digoxin
( DrugBank: Digoxin / KEGG DRUG: Digoxin )
7 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
| 8 | Huntington disease | 1 |
| 46 | Malignant rheumatoid arthritis | 5 |
| 57 | Idiopathic dilated cardiomyopathy | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 1 |
| 67 | Polycystic kidney disease | 1 |
| 210 | Single Ventricle | 2 |
2. Amyotrophic lateral sclerosis
Clinical trials : 867 / Drugs : 820 - (DrugBank : 185) / Drug target genes : 189 - Drug target pathways : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
8. Huntington disease
Clinical trials : 296 / Drugs : 245 - (DrugBank : 63) / Drug target genes : 89 - Drug target pathways : 165
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
46. Malignant rheumatoid arthritis
Clinical trials : 4,743 / Drugs : 3,042 - (DrugBank : 389) / Drug target genes : 205 - Drug target pathways : 253
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
57. Idiopathic dilated cardiomyopathy
Clinical trials : 148 / Drugs : 217 - (DrugBank : 60) / Drug target genes : 46 - Drug target pathways : 143
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
65. Primary immunodeficiency
Clinical trials : 866 / Drugs : 858 - (DrugBank : 122) / Drug target genes : 108 - Drug target pathways : 232
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
67. Polycystic kidney disease
Clinical trials : 251 / Drugs : 278 - (DrugBank : 69) / Drug target genes : 97 - Drug target pathways : 182
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
210. Single Ventricle
Clinical trials : 61 / Drugs : 70 - (DrugBank : 25) / Drug target genes : 35 - Drug target pathways : 78
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|